| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | tildrakizumab (Ilumetri®) |
| Formulation | 100 mg solution for injection |
| Reference number | 2084 |
| Indication | Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy |
| Company | Almirall Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/08/2018 |
| NICE guidance | TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |